Qin Xian, Chen Jing, Wu Long, Liu Zhisu
Department of Hepatobiliary Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, PR China.
Department of Endocrinology, Zhongnan Hospital of Wuhan University, Wuhan 430071, PR China.
Biomed Pharmacother. 2017 May;89:742-750. doi: 10.1016/j.biopha.2017.02.062. Epub 2017 Mar 6.
MicroRNAs have been verified to participate in various biological behaviors of different tumors, via multiple signaling pathways. Many kinds of microRNAs in hepatocellular carcinoma have been researched. However, miR-30b-5p hasn't been included. Our study aim at the impacts of miR-30b-5p on HCC and the pathway it mediating. The results showed miR-30b-5p was significant downregulated in HCC tissues and cell lines. With clinical data, we've discovered miR-30b-5p was correlated with several clinical pathological characteristics, such as survival time, tumor size, HBV infected, pathological stage, differentiation and intrahepatic metastasis. Also we illustrated miR-30b-5p repressed cell proliferation and cell cycle of HCC cell lines. For a further study, we figured out that miR-30b-5p mediated DNMT3A to repress proliferation, meanwhile it targeted USP37 for decelerating cell cycle. This discovery inferred miR-30b-5p a potential favorable biomarker and therapeutic target for HCC diagnosis and treatment.
微小RNA已被证实可通过多种信号通路参与不同肿瘤的各种生物学行为。肝细胞癌中的多种微小RNA已被研究。然而,miR-30b-5p尚未被纳入研究。我们的研究旨在探讨miR-30b-5p对肝癌的影响及其介导的途径。结果显示,miR-30b-5p在肝癌组织和细胞系中显著下调。通过临床数据,我们发现miR-30b-5p与多个临床病理特征相关,如生存时间、肿瘤大小、乙肝病毒感染、病理分期、分化程度及肝内转移。此外,我们还表明miR-30b-5p可抑制肝癌细胞系的细胞增殖和细胞周期。为进一步研究,我们发现miR-30b-5p通过介导DNMT3A抑制增殖,同时靶向USP37减缓细胞周期。这一发现提示miR-30b-5p可能是肝癌诊断和治疗的潜在有利生物标志物和治疗靶点。